CL2022002592A1 - Uso de agentes para el tratamiento de condiciones respiratorias - Google Patents

Uso de agentes para el tratamiento de condiciones respiratorias

Info

Publication number
CL2022002592A1
CL2022002592A1 CL2022002592A CL2022002592A CL2022002592A1 CL 2022002592 A1 CL2022002592 A1 CL 2022002592A1 CL 2022002592 A CL2022002592 A CL 2022002592A CL 2022002592 A CL2022002592 A CL 2022002592A CL 2022002592 A1 CL2022002592 A1 CL 2022002592A1
Authority
CL
Chile
Prior art keywords
agents
treatment
respiratory conditions
subject
compound
Prior art date
Application number
CL2022002592A
Other languages
English (en)
Inventor
Jay Kanes Stephen
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of CL2022002592A1 publication Critical patent/CL2022002592A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan métodos para tratar un síntoma de una condición respiratoria o una enfermedad asociada con un coronavirus, en un sujeto, que comprenden administrar al sujeto una cantidad efectiva de un agente seleccionado del grupo que consiste en el Compuesto 1 y el Compuesto 2, o una sal farmacéuticamente aceptable de los mismos.
CL2022002592A 2020-03-25 2022-09-23 Uso de agentes para el tratamiento de condiciones respiratorias CL2022002592A1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202062994805P 2020-03-25 2020-03-25
US202062994803P 2020-03-25 2020-03-25
US202063000418P 2020-03-26 2020-03-26
US202063000415P 2020-03-26 2020-03-26
US202063006672P 2020-04-07 2020-04-07
US202063006671P 2020-04-07 2020-04-07
US202063063780P 2020-08-10 2020-08-10
US202063063803P 2020-08-10 2020-08-10

Publications (1)

Publication Number Publication Date
CL2022002592A1 true CL2022002592A1 (es) 2023-04-21

Family

ID=75478347

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002592A CL2022002592A1 (es) 2020-03-25 2022-09-23 Uso de agentes para el tratamiento de condiciones respiratorias

Country Status (15)

Country Link
US (2) US20230346801A1 (es)
EP (1) EP4125921A1 (es)
JP (1) JP2023519241A (es)
KR (1) KR20220157426A (es)
CN (1) CN115551514A (es)
AU (1) AU2021241622A1 (es)
BR (1) BR112022019085A2 (es)
CA (1) CA3176854A1 (es)
CL (1) CL2022002592A1 (es)
CO (1) CO2022013777A2 (es)
IL (1) IL296645A (es)
MX (1) MX2022011804A (es)
PE (1) PE20221911A1 (es)
TW (2) TW202143977A (es)
WO (2) WO2021195297A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000008T1 (it) 2012-01-23 2020-03-13 Sage Therapeutics Inc Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
CN113527400B (zh) 2013-04-17 2024-06-28 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
ME03749B (me) 2014-11-27 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a
CN115974956A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
EP4011897A4 (en) * 2019-08-07 2024-02-21 Shanghai Hansoh Biomedical Co., Ltd. SALT AND CRYSTAL FORM OF A STEROID DERIVATIVE REGULATOR
EP4217002A4 (en) * 2020-09-25 2024-10-23 The Regents of the University of California COMPOSITIONS AND METHODS FOR THE RELIEF OF MEDICAL DISEASES
MX2023006063A (es) * 2020-11-25 2023-08-09 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central.
TW202341997A (zh) * 2022-02-28 2023-11-01 美商賽吉醫療公司 用於治療腸胃疾病或病狀之神經活性類固醇
EP4650359A1 (en) * 2022-07-28 2025-11-19 Hunan Kyf Pharmaceutical. Co., Ltd. Steroid compound for treating central nervous system disease, method for preparing same, and use and pharmaceutical composition thereof
CN119176847B (zh) * 2023-06-21 2026-05-01 北京华睿鼎信科技有限公司 一种甾类化合物及其用途、制备方法和包含该甾类化合物的药物组合物
CN116999444B (zh) * 2023-09-01 2026-03-20 山东中医药大学 四氢孕酮在制备抗流感病毒药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010060A (pt) 1999-04-29 2002-01-15 Purdue Pharma Ltd Esteróides 3<244>-hidroxi-3<225>-metoximetil-21-heterocìclo substituìdos com atividade anestésica
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
CA3152410A1 (en) 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
SMT202000008T1 (it) 2012-01-23 2020-03-13 Sage Therapeutics Inc Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
ES2973320T3 (es) 2012-11-30 2024-06-19 Univ California Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto
TR201808616T4 (tr) 2012-12-18 2018-07-23 Sage Therapeutics Inc Nöroaktif 19-alkoksi-17-ikameli steroidler, bunların ön ilaçları ve bunları kullanan tedavi yöntemleri.
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
CN113527400B (zh) * 2013-04-17 2024-06-28 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
RU2019126333A (ru) 2013-04-17 2019-10-08 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AU2014308621C1 (en) 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3188734A4 (en) * 2014-09-02 2018-01-10 The Texas A&M University System Method of treating organophosphate intoxication
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
MX2021004492A (es) 2014-10-16 2022-12-05 Sage Therapeutics Inc Composiciones para el tratamiento de trastornos del snc.
SMT202000414T1 (it) 2014-10-16 2020-09-10 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
ME03749B (me) 2014-11-27 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
WO2017087864A1 (en) 2015-11-20 2017-05-26 Sage Therapeutics, Inc. Compounds and methods of their use
RU2766155C2 (ru) 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
CN115974956A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
CA3075038A1 (en) 2017-09-07 2019-03-14 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019051477A1 (en) 2017-09-11 2019-03-14 Sage Therapeutics, Inc. METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
IL275562B2 (en) 2017-12-22 2024-07-01 Sage Therapeutics Inc Compositions and methods for treating cns disorders
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
KR102917075B1 (ko) 2018-02-11 2026-01-26 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 스테로이드 유도체 조절제, 그의 제조 방법 및 그의 용도
WO2019226515A1 (en) * 2018-05-21 2019-11-28 The University Of North Carolina At Chapel Hill Methods of inhibiting proinflammatory neuroimmune signaling and treating inflammatory disorders
CN117959309A (zh) 2018-06-12 2024-05-03 萨奇治疗股份有限公司 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
US20210177805A1 (en) * 2018-08-22 2021-06-17 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
WO2020185710A1 (en) * 2019-03-08 2020-09-17 Alairion, Inc. Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor

Also Published As

Publication number Publication date
WO2021195301A1 (en) 2021-09-30
PE20221911A1 (es) 2022-12-23
US20230346801A1 (en) 2023-11-02
WO2021195297A1 (en) 2021-09-30
IL296645A (en) 2022-11-01
TW202202146A (zh) 2022-01-16
CO2022013777A2 (es) 2022-10-11
US20230414636A1 (en) 2023-12-28
KR20220157426A (ko) 2022-11-29
CN115551514A (zh) 2022-12-30
BR112022019085A2 (pt) 2023-01-31
CA3176854A1 (en) 2021-09-30
MX2022011804A (es) 2023-03-09
JP2023519241A (ja) 2023-05-10
AU2021241622A1 (en) 2022-10-20
EP4125921A1 (en) 2023-02-08
TW202143977A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
AR119158A1 (es) Tratamientos de angioedema hereditario
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
CL2024002764A1 (es) Tratamiento de neurofibromas plexiformes asociados a neurofibromatosis tipo 1 (nf1) en pacientes pediátricos con mirdametinib
CO5590913A2 (es) Terapia de combinacion antivirica
UY39328A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
PE20230996A1 (es) Metodo para el tratamiento de afecciones asociadas a covid-19
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
AR119159A1 (es) Tratamientos de angioedema
AR119430A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal
PY1944026A (es) Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
AR074108A1 (es) Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina
CL2025003377A1 (es) Tratamiento de afecciones inflamatorias que comprende imu-856.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
AR122400A1 (es) Uso de agentes para el tratamiento de afecciones respiratorias